Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

118.81
+0.66000.56%
Pre-market: 118.69-0.1200-0.10%07:05 EDT
Volume:656.83K
Turnover:77.73M
Market Cap:9.88B
PE:-36.99
High:119.93
Open:118.60
Low:115.97
Close:118.15
52wk High:130.05
52wk Low:39.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.11
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.55
PE(LYR):-32.20

Loading ...

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss

MT Newswires Live
·
Aug 05

Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate

Benzinga Earnings
·
Aug 05

Kymera Therapeutics Q2 EPS USD -0.62

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Aug 05

Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment

Simply Wall St.
·
Aug 02

Kymera Therapeutics Inc : Deutsche Bank Initiates Coverage with Hold Rating; Target Price $120

THOMSON REUTERS
·
Jul 30

Kymera Therapeutics Schedules Quarterly Financial Results Webcast

Reuters
·
Jul 29

Kymera Therapeutics price target raised to $135 from $125 at Guggenheim

TIPRANKS
·
Jul 28

Kymera Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Terence Rooney

Reuters
·
Jul 28

Kymera Therapeutics Appoints Terence Rooney, Md, as Chief Medical Officer

THOMSON REUTERS
·
Jul 28

Press Release: Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Dow Jones
·
Jul 28

Mizuho Raises Price Target on Kymera Therapeutics to $140 From $120, Keeps Outperform Rating

MT Newswires Live
·
Jul 16

Kymera Therapeutics Inc : Mizuho Raises Target Price to $140 from $120

THOMSON REUTERS
·
Jul 16

Kymera Therapeutics Shares Fall After RBC Downgrade

MT Newswires Live
·
Jul 14

Kymera Therapeutics Cut to Sector Perform from Outperform by RBC Capital

Dow Jones
·
Jul 13

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

MT Newswires Live
·
Jul 13

Kymera Therapeutics Inc : RBC Cuts to Sector Perform from Outperform; Raises Target Price to $115 from $106

THOMSON REUTERS
·
Jul 13

Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?

Simply Wall St.
·
Jul 11